Editas Medicine Valuation
| EDIT Stock | USD 2.20 0.01 0.45% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Editas Medicine shows a prevailing Real Value of $5.0 per share. The current price of the firm is $2.2. Our model computes the value of Editas Medicine from reviewing the firm fundamentals such as Shares Owned By Institutions of 70.13 %, current valuation of (44.99 M), and Shares Owned By Insiders of 0.32 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Editas Medicine's valuation include:
Price Book 1.034 | Enterprise Value -45 M | Enterprise Value Ebitda (1.36) | Price Sales 2.9406 | Enterprise Value Revenue 1.2489 |
Undervalued
Today
Please note that Editas Medicine's price fluctuation is relatively risky at this time. Calculation of the real value of Editas Medicine is based on 3 months time horizon. Increasing Editas Medicine's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Editas Medicine's intrinsic value may or may not be the same as its current market price of 2.20, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.2 | Real 5.0 | Target 13.6 | Hype 2.16 | Naive 2.19 |
The intrinsic value of Editas Medicine's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Editas Medicine's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Editas Medicine helps investors to forecast how Editas stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Editas Medicine more accurately as focusing exclusively on Editas Medicine's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Editas Medicine's intrinsic value based on its ongoing forecasts of Editas Medicine's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Editas Medicine's closest peers.
Editas Medicine Cash |
|
Editas Valuation Trend
Editas Medicine's real value is important for investors to make better decisions and a more accurate overall view of Editas Medicine's financial worth over time. Using both Editas Medicine's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Editas Medicine Total Value Analysis
Editas Medicine is currently forecasted to have valuation of (44.99 M) with market capitalization of 181.61 M, debt of 36.54 M, and cash on hands of 452.56 M. The negative valuation of Editas Medicine may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Editas Medicine fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(44.99 M) | 181.61 M | 36.54 M | 452.56 M |
Editas Medicine Investor Information
About 70.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.03. Some equities with similar Price to Book (P/B) outperform the market in the long run. Editas Medicine recorded a loss per share of 2.54. The entity had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from Editas Medicine's historical financial statements, Editas Medicine is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Editas Medicine Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Editas Medicine has an asset utilization ratio of 15.65 percent. This implies that the Company is making $0.16 for each dollar of assets. An increasing asset utilization means that Editas Medicine is more efficient with each dollar of assets it utilizes for everyday operations.Editas Medicine Ownership Allocation
Editas Medicine holds a total of 82.55 Million outstanding shares. The majority of Editas Medicine outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Editas Medicine to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Editas Medicine. Please pay attention to any change in the institutional holdings of Editas Medicine as this could imply that something significant has changed or is about to change at the company. On May 1, 2021, Representative Donald S Beyer Jr of US Congress acquired under $15k worth of Editas Medicine's common stock.Editas Medicine Profitability Analysis
The company reported the previous year's revenue of 78.12 M. Net Loss for the year was (153.22 M) with loss before overhead, payroll, taxes, and interest of (155.25 M).About Editas Medicine Valuation
The stock valuation mechanism determines Editas Medicine's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Editas Medicine based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Editas Medicine. We calculate exposure to Editas Medicine's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Editas Medicine's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -99.5 M | -94.6 M | |
| Pretax Profit Margin | (1.96) | (2.06) | |
| Operating Profit Margin | (2.17) | (2.27) | |
| Net Loss | (1.96) | (2.06) | |
| Gross Profit Margin | (1.27) | (1.34) |
Editas Medicine Growth Indicators
Investing in growth stocks can be very risky. If the company such as Editas Medicine does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 76 M |
Editas Medicine Current Valuation Indicators
Editas Medicine's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Editas Medicine's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Editas Medicine, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Editas Medicine's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Editas Medicine's worth.Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.